Welcome to our dedicated page for STRATEGIC ASSET LEASING news (Ticker: LEAS), a resource for investors and traders seeking the latest updates and insights on STRATEGIC ASSET LEASING stock.
Strategic Asset Leasing (LEAS), operating as ANEW MEDICAL, INC., drives innovation in biotechnology through gene therapies and critical oncology solutions. This news hub provides investors and healthcare professionals with essential updates on the company's progress in treating neurodegenerative diseases, cancer therapies, and biosimilar developments.
Access timely reports on regulatory milestones, international patent approvals, and research collaborations that shape ANEW's position in global markets. Our curated news collection helps stakeholders track developments in Klotho protein applications, biosimilar biologics, and solutions addressing drug shortages.
Discover updates across three key areas: clinical trial advancements, strategic partnerships in the U.S. and Asia, and intellectual property developments supporting novel treatment platforms. Bookmark this page for verified updates on ANEW's progress in bringing cost-effective therapies to patients worldwide.
ANEW MEDICAL, INC. (OTC: LEAS) announced promising results for its s-KL gene therapy candidate targeting ALS, presented at the European Society of Cell and Gene Therapy. Utilizing an AAV9 viral vector, the therapy aims to enhance muscle function and neurological health in ALS patients by overexpressing the s-KL protein. Results from studies indicate improved motor function, increased muscle strength, and extended survival in treated models. CEO Dr. Joseph Sinkule emphasized the potential for further applications in other neuromuscular diseases. The company is awaiting FINRA's approval for a name change and reverse stock split.
ANEW MEDICAL, INC (OTC:LEAS) is set to present at the Emerging Growth Conference on January 11, 2023. The live online event will allow shareholders to interact with Founder and CEO, Dr. Joseph Sinkule, who will discuss the company’s α-Klotho protein and genetic therapy programs, starting at 11:25 AM Eastern time. Attendees can participate via a link provided and will have the option to access an archived webcast post-event. ANEW MEDICAL focuses on essential medicines and has a portfolio that includes generic oncology drugs and proprietary gene therapies.
ANEW MEDICAL, INC. (OTC: LEAS) announced the European Patent Organization's intent to grant a patent for a therapy targeting cognitive impairments related to diseases such as Alzheimer's and Parkinson's. The patent, licensed exclusively from Universitat Autonomous De Barcelona and ICREA in 2022, offers 20 years of protection against competition. Dr. Joseph Sinkule highlighted the therapy's positive results in animal models, supporting the development of treatments for age-related diseases.
ANEW MEDICAL, INC. (OTCPK:LEAS) has acquired an exclusive worldwide license from Universitat Autonomous de Barcelona for a platform technology targeting cell and gene therapy based on the α-Klotho protein and gene. This initiative aims to address age-related diseases, including ALS, Alzheimer's, and other neurodegenerative conditions. The company plans to leverage this technology to develop therapeutics that are safer and more effective, potentially transforming treatment approaches in the longevity sector.
ANEW MEDICAL, INC. (OTCPK: LEAS) has announced the acquisition of five market-approved anti-cancer drugs, including those in the "FOLFOX" and "FOLFIRI" regimens, targeted for colorectal and gastric cancers, as well as drugs for metastatic lung cancer. The drugs, critical for treating various solid tumors, address previous shortages in the market. The company plans to market these products in Europe before expanding to the U.S. Additionally, ANEW aims to establish a competitive pricing strategy, focusing on affordability while also exploring biosimilar biologics for higher margins.
Strategic Asset Leasing Inc. (OTC PINK:LEAS) announced the formation of an advisory board, beginning with the appointment of Vincent Risalvato, CEO of Pennex Foods. Risalvato brings extensive expertise in technology and business, having sold companies worth over $20 million. The company will showcase its IoT devices at the November 4-6 IoT North American tech expo, where CEO Jason Tucker will co-present with Risalvato. Additionally, Strategic is developing an e-commerce site for new IoT device sales, enhancing its market presence.
Strategic Asset Leasing (OTC PINK:LEAS) announced the launch of Leascoin, a new cryptocurrency asset, now tradeable on the GASP blockchain. This development is aimed at supporting the company's future acquisitions, including a cryptocurrency mining datacenter and a cannabis banking platform. CEO Jason Tucker emphasized that the integration of Leascoin with these acquisitions will strengthen the company's portfolio and provide clearer insights to shareholders. The company focuses on leveraging technology in the FinTech and IoT sectors to enhance shareholder value.
Strategic Asset Leasing Inc. (LEAS) announces the imminent launch of its own cryptocurrency, Leascoin, utilizing the advanced Aspire Gas (GASP) blockchain. This cryptocurrency aims to prevent mining exploits, offering a cost-effective transaction method at just 1 satoshi per byte, with transaction speeds four times faster than Bitcoin. The company is also acquiring a cryptocurrency mining datacenter and a cannabis banking platform, which synergize with Leascoin's launch. CEO Jason Tucker emphasizes the well-timed deployment of this cryptocurrency to enhance shareholder value.
